SCHEMBL183623

SCHEMBL183623

[C]#CC#CC#C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL706350 0.76
SCHEMBL142043 0.76
SCHEMBL55246 0.71
SCHEMBL8770031 0.71
SCHEMBL13617410 0.71
SCHEMBL12163216 0.71
SCHEMBL12163217 0.71
SCHEMBL28413784 0.67
SCHEMBL2532895 0.61
SCHEMBL10045979 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1081 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110004003-A1 Compound, Photochromic Material, Electronic Material, Compound Producing Method, 2,3-BIS(N,N-BIS(P-ANISYL)4-Minophenylethynyl)Dimethylfumarate Producing Method and 2,3-BIS(N,N-BIS(P-ANISYL)4-Aminophenylethynyl)Dimethylmaleate Producing method THE UNIVERSITY OF TOKYO (JP) 2011-01-06 US claimed
US-20050171078-A1 Novel azacyclic ethynyl derivatives NEUROSEARCH (DK) 2005-08-04 US claimed
US-12042479-B2 Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders INMED PHARMACEUTICALS INC. 2024-07-23 US disclosed
US-20240238427-A1 METHODS OF TREATING AN EYE DISORDER KODIAK SCIENCES INC. 2024-07-18 US disclosed
US-20240239751-A1 PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF BRIDGEBIO GENE THERAPY RESEARCH, INC. 2024-07-18 US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 US disclosed
US-20240228480-A1 PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS CURIA GLOBAL, INC. 2024-07-11 US disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 US disclosed
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. 2024-07-04 US disclosed
US-12024731-B2 Methods and enzyme catalysts for the synthesis of non-canonical amino acids CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-07-02 US disclosed
US-20240209076-A1 USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF KODIAK SCIENCES INC. 2024-06-27 US disclosed
US-20030176416-A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2003-09-18 US disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed
US-6495533-B1 TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV ONO PHARMACEUTICAL CO., LTD. (JP) 2002-12-17 US disclosed
EP-1236726-A1 TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-04 EP disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed
EP-1156054-A1 DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-11-21 EP disclosed
US-5783306-A Hyperpolarizable compounds and devices fabricated therefrom TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1998-07-21 US disclosed
US-5654471-A Process for the preparation of 4-hydroxyphenyl benzoate derivatives CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1997-08-05 US disclosed
WO-1997027049-A1 HYPERPOLARIZABLE COMPOUNDS AND DEVICES FABRICATED THEREFROM THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1997-07-31 WO disclosed